MHC-binding peptides as immunotherapeutics for cancer.
Kobayashi
H
H
Department of Immunology and Mayo Graduate School, Mayo Clinic, Rochester, MN 55905, USA.
Kennedy
R
R
Lu
J
J
Davila
E
E
Celis
E
E
D000951:Antigens, Neoplasm / Q000378:metabolism*; D002272:Carcinoembryonic Antigen / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D000939:Epitopes / Q000378:metabolism; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D000949:Histocompatibility Antigens Class II / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D066298:In Vitro Techniques; D009363:Neoplasm Proteins / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D010455:Peptides / Q000276:immunology* / Q000378:metabolism*; D011485:Protein Binding; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen; D000939:Epitopes; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D009363:Neoplasm Proteins; D010455:Peptides; D018719:Erb-b2 Receptor Tyrosine Kinases; C072012:MAGEB2 protein, human